All In Biotech

Drug Trial Radar · NCT07533175

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Type 2 Diabetes (AMAZE 2)

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 638 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

638

Planned (sponsor's estimate)

Start

Apr 13, 2026

Primary completion

Aug 7, 2028

Study completion Aug 7, 2028

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Apr 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Conditions

  • Diabetes Mellitus
  • Overweight
  • Obesity

Interventions

  • NNC0487-0111Drug

    NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

  • Placebo (matched to NNC0487-0111)Drug

    Placebo matched to NNC0487-0111 will be administered subcutaneously using PDS290 pre-filled pen-injectors to one of the body parts: thigh, abdomen or upper arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative change in body weightTime frame: From baseline (week 0) to (week 84)

Locations

73 sites in 10 countries. Site status is shown where the registry gives one.

  • Univ of Alabama Birmingham

    Birmingham, Alabama

  • Headlands Research California, LLC

    Escondido, California

  • Torrance Clinical Research Institute, Inc.

    Lomita, California

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Northeast Research Institute

    Fleming Island, Florida

  • Jacksonville Ctr Clin Res

    Jacksonville, Florida

  • Florida Institute for Clinical Research, LLC

    Orlando, Florida

  • Oviedo Medical Research, LLC

    Oviedo, Florida

  • International Diabetes Center

    Minneapolis, Minnesota

  • Southgate Medical Group, LLP

    West Seneca, New York

  • Spartanburg Medical Research

    Spartanburg, South Carolina

  • M3 Wake Research Chattanooga

    Chattanooga, Tennessee

  • UT Southwestern Med Center

    Dallas, Texas

  • PlanIt Research, PLLC

    Houston, Texas

  • National Clin Res Inc.

    Richmond, Virginia

  • Kynet Recoleta

    Buenos Aires, Argentina

  • Centro médico privado Cemaic

    Córdoba, Argentina

  • CEDIR - Centro de diagnóstico y rehabilitación Santa Fe

    Santa Fe, Argentina

  • MICA- Medicina e Investigación Cardiometabólica

    Manuel Alberti, Buenos Aires, Argentina

  • Cline Research Center

    Curitiba, Paraná, Brazil

  • PUCCAMP - Hospital e Maternidade Celso Pierro

    Campinas, São Paulo, Brazil

  • CPCLIN - Centro de Pesquisas Clínicas

    São Paulo, São Paulo, Brazil

  • Centro de Pesquisa Clínica do Hospital das Clínicas da Faculdade de Medicina da USP

    São Paulo, São Paulo, Brazil

  • Opca bolnica Karlovac

    Karlovac, Croatia

  • Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology

    Krapinske Toplice, Croatia

  • Specijalna bolnica Thalassotherapia

    Opatija, Croatia

  • Poliklinika SLAVONIJA OSIJEK

    Osijek, Croatia

  • Opca bolnica Pula

    Pula, Croatia

  • Poliklinika za oftalmologiju optometriju i neurologiju Lux

    Solin, Croatia

  • Opca bolnica Varazdin_Endocrinology

    Varaždin, Croatia

  • Poliklinika Solmed

    Zagreb, Croatia

  • DRC Kft.

    Balatonfüred, Hungary

  • Szent Margit Rendelőintézet Nonprofit Kft.

    Budapest, Hungary

  • Semmelweis Egyetem

    Budapest, Hungary

  • PVN Kutató Kft.

    Budapest, Hungary

  • Észak-Pesti Centrumkórház Honvédkórház - Diabetológia Szakrendelés

    Budapest, Hungary

  • Trantor 99 Bt

    Budapest, Hungary

  • Somogy Vármegyei Kaposi Mór Oktató Kórház

    Kaposvár, Hungary

  • Szegedi Tudomanyegyetem St Györgyi Albert Klinikai Központ

    Szeged, Csongrád-Csanád, Hungary

  • IRCCS Ospedale San Raffaele Milano

    Milan, Italy

Showing 40 of 73 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.